Posts Tagged ‘Saxenda’

Wegovy: Disrupting Obesity Care and Supply Chains

December 18, 2021 — Novo Nordisk has a problem. Yesterday its stock lost 16 billion dollars from its value. This is because the company is hitting some bumps in its journey through the uncharted territory of obesity care. For more than a decade now, Novo has been investing in a genuine effort to meet a need for better obesity […]

Tirzepatide Shows Good Weight Outcomes in Diabetes

October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]

New Study in NEJM: Controlling versus Losing Weight

May 6, 2021 — Weight loss is a minor part of obesity care. It’s blindingly obvious, but most people have a tough time wrapping their heads around this basic fact. A new study in the New England Journal of Medicine today tells this story in a very elegant way. It’s all about controlling weight over time. Getting Weight Loss […]

Semaglutide for Obesity: A Game Changer?

February 11, 2021 — A new study of semaglutide in the New England Journal of Medicine is causing quite a stir in the news. (If you can get past impeachment headlines.) In fact, both experts and headline writers are calling semaglutide for obesity a game changer. Meanwhile, the only sour note comes from the futility school of obesity care. […]

FDA Approves Saxenda (liraglutide) for Obesity in Teens

December 5, 2020 — Late on Friday, Novo Nordisk announced FDA approval for Saxenda (liraglutide 3mg) to treat obesity in teens. This marks the second such drug approved in for youth in little more than a week. Setmelanotide received approval last week for children as young as six. Make no mistake about it, we are making progress in expanding […]

OW2020: High Expectations for Semaglutide in Obesity

November 10, 2020 — Saxenda (liraglutide) is on the brink of becoming a billion dollar drug for obesity. Yet its effectiveness in obesity is modest. On average, a person taking it might expect that their weight would go down by about eight percent. Of course, some people will have a much bigger benefit. But others will have less or […]

Semaglutide Coming on Strong

February 7, 2020 — The decade just past brought quite a bit of change in drugs used to treat obesity. At the beginning of the decade, options were few. Prescribing was almost nil. Now we have five new drugs for obesity. For type 2 diabetes, weight-sparing drugs have taken a dominant role in prescribing. One of those drugs, liraglutide, […]

ObesityWeek: Emerging Anti-Obesity Medicines

November 5, 2019 — Success begets success. That’s a core message we’re taking away from a late-breaking forum on emerging anti-obesity medicines. Pharmaceutical researchers reviewed an impressive range of innovations that promise to set a higher bar for effective obesity care. All of this came before ObesityWeek kicks into high gear today. Building Upon Success Mads Tang-Christensen opened the […]

Why Orexigen Crashed and Novo Nordisk Soars

March 13, 2018 — It’s a tale of two obesity drug makers. One – Orexigen – filed for Chapter 11 bankruptcy yesterday. Orexigen markets Contrave, a combination drug made from bupropion and naltrexone. The other company – Novo Nordisk – is building upon the early success of its obesity drug, Saxenda (liraglutide 3mg). Why are the fortunes of these two companies so […]

Semaglutide Clears Two Important Hurdles

October 19, 2017 — This is a big week for semaglutide – a promising cousin of liraglutide. Research is ongoing to figure out just how good it will be in both type 2 diabetes and obesity. And the milestones this week were all about diabetes. But you can find some encouragement for the obesity indication, too. Unanimous Support from FDA’s […]